Jose M. Marcelino

Monte, 2829511, Portugal

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

An HIV-1/HIV-2 Chimeric Envelope Glycoprotein Generates Binding and Neutralising Antibodies against HIV-1 and HIV-2 Isolates.

An HIV-1/HIV-2 Chimeric Envelope Glycoprotein Generates Binding and Neutralising Antibodies against HIV-1 and HIV-2 Isolates.

Journal: International journal of molecular sciences

Published: April 03, 2023

Long-Term and Low-Level Envelope C2V3 Stimulation by Highly Diverse Virus Isolates Leads to Frequent Development of Broad and Elite Antibody Neutralization in HIV-1-Infected Individuals.

Long-Term and Low-Level Envelope C2V3 Stimulation by Highly Diverse Virus Isolates Leads to Frequent Development of Broad and Elite Antibody Neutralization in HIV-1-Infected Individuals.

Journal: Microbiology spectrum

Published: November 29, 2022

Standardised arthropod (Arthropoda) inventory across natural and anthropogenic impacted habitats in the Azores archipelago.

Standardised arthropod (Arthropoda) inventory across natural and anthropogenic impacted habitats in the Azores archipelago.

Journal: Biodiversity data journal

Published: December 17, 2020

Antibody response against selected epitopes in the HIV-1 envelope gp41 ectodomain contributes to reduce viral burden in HIV-1 infected patients.

Antibody response against selected epitopes in the HIV-1 envelope gp41 ectodomain contributes to reduce viral burden in HIV-1 infected patients.

Journal: Scientific reports

Published: October 28, 2020

A Prime-Boost Immunization Strategy with Vaccinia Virus Expressing Novel gp120 Envelope Glycoprotein from a CRF02_AG Isolate Elicits Cross-Clade Tier 2 HIV-1 Neutralizing Antibodies.

A Prime-Boost Immunization Strategy with Vaccinia Virus Expressing Novel gp120 Envelope Glycoprotein from a CRF02_AG Isolate Elicits Cross-Clade Tier 2 HIV-1 Neutralizing Antibodies.

Journal: Vaccines

Published: March 02, 2020

Potency of HIV-2-specific antibodies increase in direct association with loss of memory B cells.

Potency of HIV-2-specific antibodies increase in direct association with loss of memory B cells.

Journal: AIDS (London, England)

Published: October 14, 2017

Evolution of the human immunodeficiency virus type 2 envelope in the first years of infection is associated with the dynamics of the neutralizing antibody response.

Evolution of the human immunodeficiency virus type 2 envelope in the first years of infection is associated with the dynamics of the neutralizing antibody response.

Journal: Retrovirology

Published: April 02, 2013

An ancestral HIV-2/simian immunodeficiency virus peptide with potent HIV-1 and HIV-2 fusion inhibitor activity.

An ancestral HIV-2/simian immunodeficiency virus peptide with potent HIV-1 and HIV-2 fusion inhibitor activity.

Journal: AIDS (London, England)

Published: January 18, 2013

Resistance to antibody neutralization in HIV-2 infection occurs in late stage disease and is associated with X4 tropism.

Resistance to antibody neutralization in HIV-2 infection occurs in late stage disease and is associated with X4 tropism.

Journal: AIDS (London, England)

Published: November 16, 2012

Memory B-cell depletion is a feature of HIV-2 infection even in the absence of detectable viremia.

Memory B-cell depletion is a feature of HIV-2 infection even in the absence of detectable viremia.

Journal: AIDS (London, England)

Published: June 15, 2012

Showing 1-10 of 10

Last Updated: 09/26/2026